We are live on ! Find out more
NVS icon

Novartis

925 hedge funds and large institutions have $21.4B invested in Novartis in 2015 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 335 increasing their positions, 349 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% less ownership

Funds ownership: 9.84%9.81% (-0.03%)

2% less call options, than puts

Call options by funds: $69.6M | Put options by funds: $71M

4% less repeat investments, than reductions

Existing positions increased: 335 | Existing positions reduced: 349

2% less funds holding

Funds holding: 943925 (-18)

3% less funds holding in top 10

Funds holding in top 10: 6159 (-2)

7% less capital invested

Capital invested by funds: $22.9B → $21.4B (-$1.51B)

19% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 53

Holders
925
Holders Change
-18
Holders Change %
-1.91%
% of All Funds
25.82%
Holding in Top 10
59
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-3.28%
% of All Funds
1.65%
New
43
Increased
335
Reduced
349
Closed
53
Calls
$69.6M
Puts
$71M
Net Calls
-$1.35M
Net Calls Change
-$46.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$4.2B -$223M -2,507,998 -5%
Primecap Management
2
Primecap Management
California
$1.91B -$131M -1,475,743 -6%
BBHC
3
Brown Brothers Harriman & Co
New York
$854M -$43M -483,646 -4%
Wells Fargo
4
Wells Fargo
California
$699M -$11.9M -134,058 -2%
Franklin Resources
5
Franklin Resources
California
$648M +$337M +3,792,015 +93%
Fisher Asset Management
6
Fisher Asset Management
Washington
$564M +$7.7M +86,569 +1%
Bank of America
7
Bank of America
North Carolina
$519M +$331M +3,717,941 +144%
UBS Group
8
UBS Group
Switzerland
$458M -$14.6M -163,913 -3%
Loomis, Sayles & Company
9
Loomis, Sayles & Company
Massachusetts
$423M +$32.1M +360,385 +8%
IC
10
Institutional Capital
Illinois
$353M +$227M +2,551,724 +147%
Northern Trust
11
Northern Trust
Illinois
$326M -$62.4M -700,709 -15%
State Street
12
State Street
Massachusetts
$308M +$331M +3,718,520 +24,558%
MNA
13
Manning & Napier Advisors
New York
$256M +$148M +1,667,084 +116%
Parnassus Investments
14
Parnassus Investments
California
$243M +$11.1M +124,324 +4%
Mawer Investment Management
15
Mawer Investment Management
Alberta, Canada
$231M +$37.6M +422,167 +18%
ClearBridge Investments
16
ClearBridge Investments
New York
$219M -$1.38M -15,500 -0.6%
Lazard Asset Management
17
Lazard Asset Management
New York
$211M +$5.99M +67,287 +3%
Capital Research Global Investors
18
Capital Research Global Investors
California
$208M
EARNEST Partners
19
EARNEST Partners
Georgia
$205M +$949K +10,660 +0.4%
Invesco
20
Invesco
Georgia
$202M -$29.9M -335,482 -12%
Morgan Stanley
21
Morgan Stanley
New York
$193M -$12.9M -145,033 -6%
Boston Partners
22
Boston Partners
Massachusetts
$171M -$6.7M -75,270 -4%
Aristotle Capital Management
23
Aristotle Capital Management
California
$167M +$920K +10,337 +0.5%
Renaissance Technologies
24
Renaissance Technologies
New York
$155M +$49.2M +553,313 +42%
Macquarie Group
25
Macquarie Group
Australia
$153M +$1.85M +20,750 +1%

NVS Hedge Fund Activity: Q3 2015 in Review

925 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2015, worth a combined $21.4B — down 6.6% from $22.9B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of NVS and 43 opened new positions — a net loss of 10 holders — while 349 trimmed existing stakes and 335 added.

The largest buyer was Franklin Resources, adding an estimated $337M. The largest seller was Fidelity Investments, cutting an estimated $398M.

  • 925 institutional investors held Novartis (NVS) as of Q3 2015, down from 943 in Q2 2015.
  • Funds reported $21.4B of Novartis stock for Q3 2015, down 6.6% quarter-over-quarter.
  • 43 funds opened new Novartis positions in Q3 2015 and 53 closed out, a net change of -10 holders.
  • The largest Novartis buyer in Q3 2015 was Franklin Resources, an estimated $337M added.
  • The largest Novartis seller in Q3 2015 was Fidelity Investments, an estimated $398M sold.

Based on aggregated 13F filings for Q3 2015.